Acurx Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Acurx Pharmaceuticals's earnings have been declining at an average annual rate of -21.4%, while the Biotechs industry saw earnings growing at 7.7% annually.
Key information
-21.4%
Earnings growth rate
-1.7%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | n/a |
| Return on equity | -617.0% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Acurx Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -16 | 10 | 7 |
| 30 Jun 24 | 0 | -17 | 10 | 7 |
| 31 Mar 24 | 0 | -16 | 9 | 7 |
| 31 Dec 23 | 0 | -15 | 9 | 6 |
| 30 Sep 23 | 0 | -13 | 7 | 6 |
| 30 Jun 23 | 0 | -13 | 7 | 6 |
| 31 Mar 23 | 0 | -12 | 7 | 5 |
| 31 Dec 22 | 0 | -12 | 7 | 5 |
| 30 Sep 22 | 0 | -11 | 7 | 4 |
| 30 Jun 22 | 0 | -13 | 9 | 4 |
| 31 Mar 22 | 0 | -14 | 11 | 3 |
| 31 Dec 21 | 0 | -13 | 11 | 2 |
| 30 Sep 21 | 0 | -11 | 10 | 2 |
| 30 Jun 21 | 0 | -8 | 7 | 1 |
| 31 Mar 21 | 0 | -5 | 3 | 2 |
| 31 Dec 20 | 0 | -5 | 2 | 2 |
Quality Earnings: 3ZO is currently unprofitable.
Growing Profit Margin: 3ZO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 3ZO is unprofitable, and losses have increased over the past 5 years at a rate of 21.4% per year.
Accelerating Growth: Unable to compare 3ZO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 3ZO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: 3ZO has a negative Return on Equity (-616.96%), as it is currently unprofitable.